Appendix Table 1.
SVR, by Group, for Study Participants Overall and for Those Receiving a Combination DAA Regimen*
| Group | Overall | Combination DAA Regimen | ||||
|---|---|---|---|---|---|---|
| Patients, n | SVR, n (%) | SVR, 95% CI, % | Patients, n | SVR, n (%) | SVR, 95% CI, % | |
| Overall | ||||||
| DOT | 51 | 50 (98) | 90 to 100 | 36 | 36 (100) | 90 to 100 |
| GT | 48 | 45 (94) | 83 to 99 | 40 | 38 (95) | 83 to 99 |
| SIT | 51 | 46 (90) | 79 to 97 | 39 | 35 (90) | 76 to 97 |
| Total | 150 | 141 (94) | 89 to 97 | 115 | 109 (95) | 89 to 98 |
| Difference in SVR (95% CI), percentage points | Difference in SVR (95% CI), percentage points | |||||
| Comparison | ||||||
| DOT vs. GT | – | 4 (–7 to 16) | – | 5 (–8 to 18) | ||
| DOT vs. SIT | – | 8 (–4 to 20) | – | 10 (–4 to 25) | ||
| GT vs. SIT | – | 4 (–10 to 17) | – | 5 (–10 to 21) | ||
DAA = direct-acting antiviral; DOT = directly observed therapy; GT = group treatment; SIT = self-administered individual treatment; SVR = sustained virologic response.
*
No significant differences in SVR were found across the 3 groups (P = 0.152) among all participants or among those receiving combination DAA treatment (P = 0.056), on the basis of multivariable exact logistic regression adjusting for site and the 3 stratifying variables. No missing data were observed for this analysis.